Dec 1 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:
REGENERON AND TESSERA THERAPEUTICS TO JOINTLY DEVELOP TSRA-196, AN INVESTIGATIONAL GENE EDITING THERAPY FOR ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
REGENERON PHARMACEUTICALS INC - TESSERA ELIGIBLE FOR ADDITIONAL $125 MILLION MILESTONE PAYMENTS
Source text: ID:nGNX3fwBwZ
Further company coverage: REGN.O
((Reuters.Briefs@thomsonreuters.com;))